Perimenopause mental health: what the research says about depression and anxiety

Perimenopause mental health: what the research says about depression and anxiety

Nearly 29% of women in early perimenopause show clinically significant psychological distress - almost double the rate seen in premenopausal women of the same age, according to a 2023 systematic review published in PubMed Central. For many women, this shift arrives without warning. Energy stays low, sleep fragments, and moods swing in ways that feel out of proportion to circumstances. Depression and anxiety during the menopausal transition are not unusual. They are well-documented physiological responses to hormonal change, and they deserve the same attention as the physical symptoms of menopause.

The hormonal fluctuations of perimenopause directly affect the brain's chemistry. Estrogen influences serotonin, dopamine, and GABA - the neurotransmitters that regulate mood, stress tolerance, and emotional stability. When estrogen levels become erratic, as they do throughout the menopausal transition, these pathways are disrupted. Adaptogens such as ashwagandha and rhodiola, calming amino acids such as L-theanine, and minerals such as magnesium work at the level of the nervous system and the stress hormone axis to support resilience during this phase.

This article explains what perimenopause does to the brain, why depression and anxiety emerge during this phase, and what evidence-based strategies can help you maintain emotional balance through the transition.

Point Details
Prevalence of mood symptoms during perimenopause A 2023 systematic review found that nearly 29% of early perimenopausal women experienced clinically significant psychological distress, compared with approximately 21% in premenopausal women.
Estrogen and neurotransmitters Estrogen directly regulates serotonin, dopamine, and GABA pathways. Erratic estrogen fluctuations — not just low estrogen — disrupt these systems and increase vulnerability to depression and anxiety.
FIGO 2026 recommendations A March 2026 FIGO consensus published in the International Journal of Gynecology & Obstetrics identified early detection of mental health deterioration as a clinical priority for women in the menopausal transition.
HPA axis dysregulation Perimenopause increases cortisol reactivity. Elevated cortisol sustained over time worsens anxiety, fragments sleep, and reduces resilience to everyday stress.
Ashwagandha clinical evidence A 2023 double-blind, placebo-controlled trial found that standardised ashwagandha extract significantly reduced perceived stress, generalised anxiety, and morning cortisol levels compared to placebo.
Combination support is more effective Research consistently shows that adaptogens, calming amino acids, and targeted minerals work better together than any single ingredient in isolation for nervous system support.


Understanding perimenopause mental health and its connection to menopause

The menopausal transition begins years before the final menstrual period. During perimenopause, which typically starts in the early to mid-40s and can last four to ten years, ovarian hormone production becomes unpredictable. Estrogen and progesterone do not simply decline in a smooth, linear way - they fluctuate widely, surging and dropping in patterns that the brain registers as stress.

Estrogen has a well-established role in brain function. Receptors for estrogen are found throughout the limbic system - the area governing emotions, memory, and stress response - as well as in the hippocampus and prefrontal cortex. Estrogen supports the synthesis and activity of serotonin, the neurotransmitter most closely associated with mood regulation. It also influences dopamine and GABA, which govern motivation, reward, and the brain's ability to calm itself down. When estrogen fluctuates erratically, all of these systems are affected at once.

Progesterone plays its own role. As perimenopause progresses, progesterone declines before estrogen does. Progesterone's metabolites act on GABA receptors in the brain in ways that produce calming, sleep-promoting effects. When progesterone drops, this calming influence is withdrawn. The result is an increased baseline of anxiety, irritability, and sleep disruption that many women experience years before they would consider themselves "in menopause."

A March 2026 consensus report by FIGO - published by Khadilkar et al. in the International Journal of Gynecology & Obstetrics - identified early detection of mental health deterioration as a clinical priority during the menopausal transition. The expert panel noted that women with pre-existing mental health conditions are at particular risk, but also confirmed that new-onset depression and anxiety during perimenopause are common in women with no prior psychiatric history.

Understanding this biological context matters. Mood changes during perimenopause are not a signal that something is wrong with a woman's coping ability. They reflect a real shift in brain chemistry driven by hormonal change. Recognising that mechanism is the first step toward addressing it effectively.

  • Erratic estrogen fluctuation (not simply low estrogen) disrupts serotonin and dopamine signalling
  • Declining progesterone reduces GABA-mediated calming effects in the brain
  • Increased cortisol reactivity raises baseline anxiety and reduces stress resilience
  • Sleep disruption - often caused by night sweats and hormonal shifts - amplifies mood instability
  • Pre-existing history of depression or postnatal depression increases vulnerability during perimenopause
  • Psychosocial stressors common to midlife (career pressure, caregiving, relationship changes) compound the biological load

Common causes of mood changes and how hormones affect your emotional wellbeing

Mood instability during perimenopause rarely has a single cause. It reflects the intersection of hormonal biology, nervous system function, sleep quality, and the cumulative weight of daily stress. According to a 2023 systematic review published in PubMed Central, women in perimenopause are significantly more likely to meet clinical criteria for depression and anxiety than their premenopausal counterparts - with some clinic-based studies reporting that up to 28.7% of perimenopausal women aged 40 to 58 met diagnostic criteria for a depressive disorder.

The hypothalamic-pituitary-adrenal (HPA) axis sits at the centre of many of these changes. This is the system that regulates the body's response to stress by controlling cortisol release. Estrogen normally helps regulate HPA axis sensitivity. As estrogen becomes erratic during perimenopause, the HPA axis can become dysregulated - releasing cortisol more readily and at higher levels in response to stressors that would previously have been manageable. Sustained elevated cortisol contributes directly to anxiety, poor sleep, low mood, and brain fog.

Progesterone's withdrawal compounds this further. The neurosteroid allopregnanolone, derived from progesterone, has direct anxiolytic effects on the brain's GABA-A receptors. As progesterone declines, allopregnanolone levels fall with it - and that natural calming buffer disappears. For women who are already sensitive to progesterone fluctuation, this change can be felt acutely.

Cause Mechanism Impact on mood and anxiety
Erratic estrogen fluctuation Disrupts serotonin synthesis and receptor sensitivity; affects dopamine activity in reward pathways Low mood, emotional blunting, irritability, reduced motivation
Declining progesterone Reduces allopregnanolone, which normally activates GABA-A receptors and produces calming effects Increased baseline anxiety, irritability, difficulty winding down
HPA axis dysregulation Estrogen normally moderates cortisol response; its fluctuation removes this buffer Heightened stress reactivity, feeling overwhelmed, persistent tension
Sleep disruption Night sweats and hormonal changes interrupt sleep architecture, reducing REM and deep sleep Worsens mood regulation, increases anxiety, reduces emotional resilience
Thyroid function changes Perimenopause can unmask subclinical thyroid dysfunction, which independently affects mood Fatigue, low mood, cognitive slowness that can mimic or amplify depression
  • Nutritional deficiencies - particularly magnesium and B vitamins - that are common in midlife women reduce the nervous system's capacity to regulate stress
  • Reduced physical activity during busy midlife years lowers the brain's natural endorphin and BDNF production
  • Social isolation or reduced support networks amplify the experience of psychological symptoms
  • Perceptions of menopause as a negative life event are associated with worse mental health outcomes, independent of symptom severity

Nutrients and strategies that address perimenopause mental health after 40

Supporting mental health during perimenopause requires addressing the nervous system at multiple levels: the stress hormone axis, the neurotransmitter environment, sleep quality, and the body's basic nutritional resilience. The following ingredients have clinical or mechanistic evidence relevant to mood and anxiety in midlife women.

Ashwagandha (Withania somnifera)

Ashwagandha is one of the most researched adaptogens for stress and anxiety. It works primarily by moderating cortisol output and regulating HPA axis reactivity - the same system that becomes dysregulated during perimenopause. A 2023 double-blind, placebo-controlled trial published on PubMed found that a standardised ashwagandha root extract significantly reduced perceived stress scores, generalised anxiety, and morning salivary cortisol compared with placebo. Participants also reported improvements in sleep quality and overall wellbeing. For perimenopausal women whose stress reactivity has increased, ashwagandha addresses the hormonal root of the problem rather than masking symptoms.

Rhodiola rosea

Rhodiola is a Siberian adaptogen studied specifically in the context of stress-induced fatigue and burnout. Its active compounds - rosavins and salidroside - influence serotonin and dopamine transport in the brain. Clinical trials have found rhodiola reduces symptoms of stress-related burnout and improves emotional resilience in adults experiencing chronic, low-level stress. For perimenopausal women managing multiple demands alongside shifting hormones, rhodiola supports the capacity to respond rather than react.

L-Theanine

L-Theanine is an amino acid found in green tea that promotes calm alertness without sedation. It increases GABA activity in the brain and raises alpha wave activity - the mental state associated with relaxed focus. Unlike sedatives, L-theanine does not impair cognitive function. It is particularly relevant for women experiencing anxiety that peaks in the evenings or interferes with falling asleep, a pattern common in perimenopause.

GABA

GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter. It reduces neuronal excitability and is the target of many pharmaceutical anti-anxiety agents. The decline in progesterone-derived allopregnanolone during perimenopause reduces natural GABA-mediated calming. Supplemental GABA supports the inhibitory system directly, helping to reduce the persistent tension and hyperarousal that many perimenopausal women describe.

Magnesium glycinate

Magnesium is involved in over 300 enzymatic processes in the body, including those that regulate the stress response and neurotransmitter synthesis. Magnesium glycinate is the chelated form most readily absorbed by the body and least likely to cause digestive discomfort. Low magnesium status is consistently associated with increased anxiety and poor sleep quality. The glycinate form also provides glycine, which itself has calming effects on the central nervous system.

Vitamin B1 (thiamine)

Vitamin B1 supports glucose metabolism in the brain and is necessary for the synthesis of acetylcholine, the neurotransmitter involved in memory, focus, and the parasympathetic nervous system's "rest and digest" response. Perimenopause-related stress increases thiamine demand. Adequate B1 supports the nervous system's capacity to shift out of a fight-or-flight state - an important mechanism for women whose baseline tension has risen during the transition.

Pro tip: Take adaptogen-based supplements consistently for at least six to eight weeks before evaluating results. Ashwagandha and rhodiola work by gradually modulating the HPA axis, not by producing immediate sedation. Inconsistent use significantly reduces their effectiveness.

Comparing natural approaches with other treatments for menopause mood changes

Women in perimenopause have more options for addressing mood and anxiety than at any previous point in medical history. The evidence base for both pharmaceutical and non-pharmaceutical interventions has grown substantially. The choice between approaches depends on symptom severity, personal health history, and individual preference — and many women find that combining strategies produces better outcomes than any single approach alone.

Hormone therapy directly addresses the hormonal cause of perimenopausal mood changes. Antidepressants are effective for moderate to severe depression and may be appropriate when mood symptoms are disabling. Natural and lifestyle approaches work well for mild to moderate symptoms and are often used as a foundation alongside medical treatment.

Approach Pros Considerations Best for
Menopausal hormone therapy (MHT) Addresses hormonal root cause; strong evidence for mood improvement in perimenopause Requires medical assessment; not appropriate for all women; timing matters Women with moderate to severe symptoms, particularly if vasomotor symptoms also present
Antidepressants (SSRIs/SNRIs) Strong evidence for clinical depression and anxiety; also reduce hot flashes Side effects including sexual dysfunction and weight changes; not addressing hormonal cause directly Women with moderate to severe depression or anxiety, or those for whom MHT is contraindicated
Adaptogens and targeted nutrients Support HPA axis and neurotransmitter balance; well-tolerated; no prescription required Work best for mild to moderate symptoms; require consistent use over 6-8 weeks Women with mild to moderate mood and anxiety symptoms; also as supportive layer alongside MHT
Cognitive behavioural therapy (CBT) Reframes relationship with symptoms; durable results; no pharmacological side effects Requires ongoing time commitment; less accessible due to cost and availability Women who want to build psychological tools; particularly effective for anxiety and sleep disturbance
Lifestyle modification (exercise, sleep hygiene, nutrition) Free, accessible, and evidence-based; improves multiple symptoms simultaneously Requires consistency; may not be sufficient alone for moderate to severe symptoms All women as a foundation; particularly effective combined with supplement support

 

The most effective approach for most perimenopausal women is not a single intervention but a layered strategy. Lifestyle foundations - regular physical activity, consistent sleep timing, and a diet that supports blood sugar stability - reduce the physiological burden on the nervous system. Adaptogen and nutrient support addresses the biochemical environment. Therapy builds cognitive and emotional tools. Medical treatment steps in when symptoms reach clinical severity.

The FIGO 2026 recommendations explicitly call for early identification of mental health deterioration during perimenopause and advocate for a comprehensive, individualised response - one that does not default immediately to pharmaceutical intervention for mild symptoms but also does not delay medical support when it is clinically warranted.

Pro tip: Track your mood, sleep, and stress levels for four weeks before discussing options with a healthcare provider. A simple daily log with a one-to-ten rating for each takes two minutes and gives your doctor far more to work with than a single appointment's worth of conversation.

  • Know when to seek professional evaluation:
  • Persistent low mood lasting more than two weeks that does not lift with usual self-care strategies
  • Anxiety that significantly limits daily functioning or triggers avoidance of normal activities
  • Sleep disruption severe enough to affect work performance or relationships
  • Thoughts of self-harm or hopelessness - seek support immediately
  • Sudden onset of severe mood symptoms, which may signal a thyroid or other medical issue requiring investigation
  • Symptoms that worsen despite consistent lifestyle and supplement interventions over 8-12 weeks

Discover natural support for menopause well-being

Supporting the nervous system through perimenopause works best when multiple mechanisms are addressed together rather than one at a time. Botavive Tranquility combines ashwagandha, rhodiola, L-theanine, GABA, magnesium glycinate, and vitamin B1 - ingredients selected for their roles in cortisol regulation, GABA activity, and nervous system resilience. Each ingredient is included at a meaningful dose rather than spread thin across a long ingredient list.

Tranquility is not a sedative and it is not designed to mask symptoms. It supports the physiological systems that perimenopause disrupts: the stress hormone axis, the brain's inhibitory neurotransmitter environment, and the body's baseline capacity to move out of fight-or-flight. That makes it a practical foundation for women managing mild to moderate mood and anxiety shifts during the menopausal transition.

Shop Botavive Tranquility on Amazon

Frequently asked questions

Why does depression appear specifically during perimenopause if a woman has never experienced it before?

Estrogen modulates serotonin synthesis and receptor sensitivity, progesterone metabolites calm GABA receptors, and both hormones regulate HPA axis reactivity. During perimenopause, all three of these systems are disrupted simultaneously for the first time. A woman with no prior psychiatric history can experience clinically significant depression or anxiety solely as a result of this hormonal shift. The 2026 FIGO consensus paper confirmed that new-onset mood disorders during the menopausal transition are common and should not be attributed to psychological weakness or dismissed as a normal part of ageing.

How long before nutritional and adaptogen support produces noticeable results?

Most women notice early changes in stress tolerance and sleep quality within two to four weeks of consistent use. Meaningful improvements in baseline mood and anxiety typically take six to eight weeks. This timeline reflects the mechanism - adaptogens such as ashwagandha and rhodiola gradually recalibrate the HPA axis rather than producing immediate pharmaceutical effects. Consistency matters more than the specific timing of each dose.

Is one ingredient enough, or is a combination approach more effective?

The research consistently supports combination approaches. Ashwagandha addresses cortisol and HPA axis reactivity, while L-theanine and GABA work more directly on the brain's inhibitory neurotransmitter system. Magnesium and B vitamins support the enzymatic processes that underpin both systems. Using all of these together covers multiple pathways simultaneously, which more closely matches the multi-system nature of perimenopausal mood disruption than any single ingredient can.

Will mood symptoms reverse when menopause is complete, or does treatment simply manage them in the interim?

For many women, mood instability is most pronounced during perimenopause - when hormonal fluctuations are at their most erratic - and reduces after the final menstrual period as hormone levels stabilise at a lower but more consistent level. Some women do find that symptoms resolve naturally in postmenopause. Others continue to benefit from ongoing support. The trajectory varies by individual and is influenced by baseline mental health history, lifestyle, and the degree of hormonal change.

What is the difference between perimenopause depression and clinical depression?

Perimenopause-related depression refers to depressive episodes that arise in the context of the menopausal transition and are driven primarily by hormonal disruption of neurotransmitter systems. Clinical depression (major depressive disorder) is diagnosed on symptom criteria and may or may not be hormonally triggered. In practice, the symptoms overlap considerably, and perimenopause-related depression meets clinical criteria for depression in many cases. The distinction matters primarily for treatment planning: hormone therapy has specific evidence for improving perimenopause-related mood symptoms that it does not have for depression unrelated to hormonal change.

Sources

  1. Daley A, Stokes-Lampard H, Thomas A, MacArthur C (2023) — "Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review" — pmc.ncbi.nlm.nih.gov/articles/PMC10088347/
  2. Khadilkar S, Divakar H, Benedetto C et al. (2026) — "FIGO best practice recommendations for the mental health of women at menopausal age" — obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.70943
  3. Verma N et al. (2023) — "A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: Results from a randomized, double-blind, placebo-controlled study" — pubmed.ncbi.nlm.nih.gov/37832082/

Related articles

Previous post Next post
Back to blog